$16.39−0.47 (−2.79%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Arcus Biosciences (RCUS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
20 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 36% below its peak, net margin −142.9%. Worth your attention in FY25: Share count (+45.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼4.3%
247.0
FY21→FY25CAGR −10.4%/yr
Net income ($M)▼24.7%
−353.0
FY21→FY25CAGR —
Free cash flow ($M)▼175.0%
−484.0
FY21→FY25CAGR —
Diluted EPS▼4.8%
−3.29
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+45.1%
74.0mn → 107.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$2.0M
−66.7% YoY in FY25 · 0.8% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-143¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -142.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 100.0 | 247.0 | 258.0 | 117.0 | 112.0 | 383.0 | ▼4.3% | −10.4% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 383.0 | — | — |
Research & development | 473.0 | 523.0 | 448.0 | 340.0 | 288.0 | 257.0 | ▲16.7% | +19.4% |
Selling, general & admin | 102.0 | 110.0 | 120.0 | 117.0 | 104.0 | 72.0 | ▼8.3% | +11.2% |
Total operating expenses | 575.0 | 633.0 | 588.0 | 457.0 | 392.0 | 329.0 | ▲7.7% | +17.8% |
Operating incomefeeds ROC rank | −475.0 | −386.0 | −330.0 | −340.0 | −280.0 | 54.0 | ▼17.0% | — |
Other income, net | 22.0 | 33.0 | 48.0 | 39.0 | 14.0 | 1.0 | — | — |
Pretax income | −453.0 | −353.0 | −282.0 | −301.0 | −266.0 | 55.0 | ▼25.2% | — |
Income tax | — | 0.0 | 1.0 | 6.0 | 1.0 | 2.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −453.0 | −353.0 | −283.0 | −307.0 | −267.0 | 53.0 | ▼24.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.62 | −3.29 | −3.14 | −4.15 | −3.71 | — | ▼4.8% | — |
Diluted shares (mn) | 127.40 | 107.40 | 90.10 | 74.00 | 72.00 | 74.00 | ▲19.2% | +9.8% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −475.0% | −156.3% | −127.9% | −290.6% | −250.0% | 14.1% | ▼28.4pp | −170.4pp |
Net margin5th pct in Healthcare | −453.0% | −142.9% | −109.7% | −262.4% | −238.4% | 13.8% | ▼33.2pp | −156.8pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Arcus Biosciences' revenue last fiscal year?
Arcus Biosciences reported revenue of $247.0M in fiscal 2025, down 4.3% from fiscal 2024.
What was Arcus Biosciences' net income?
Arcus Biosciences reported net income of −$353.0M in fiscal 2025, a net margin of −142.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

